In a major regulatory development, the Competition Commission of India (CCI) recently dismissed antitrust allegations against 12 super-specialty hospitals. Consequently, the CCI closes hospital probe that spanned over ten years in Delhi. Specifically, the regulator rejected the Director General’s (DG) findings of overpricing. Those findings previously accused these private healthcare facilities of abusing their dominant market position.

Why the CCI Closes Hospital Probe

The DG had alleged that the hospitals engaged in unfair pricing. For example, the investigation focused on diagnostic tests, medical consumables, and room tariffs. However, the Commission disagreed with this narrow market definition. It ruled that hospital services are bundled packages. Therefore, patients seek integrated treatment rather than individual commodities.

Furthermore, the watchdog compared hospital services with standalone facilities. It noted that hospital rooms require clinical equipment. Thus, these rooms are not comparable to standard hotel accommodations. Similarly, hospital labs operate continuously to provide urgent diagnostic care. As a result, they incur higher operational costs than standalone labs.

Understanding the United Brands Standard

Under Section 4 of the Competition Act, excessive pricing alone is not illegal. Instead, the law requires proof of unfairness. To determine this, the CCI applied the two-stage test from the United Brands case. This test requires establishing both an excessive limb and an unfair limb.

However, the DG failed to prove both requirements. The regulatory body observed that charging higher prices does not automatically mean abuse of dominance. In addition, hospitals are allowed to sell items within the Maximum Retail Price (MRP). Consequently, the Commission closed the proceedings and cleared all 12 hospitals of the charges.

Frequently Asked Questions

Q1: Why did the CCI dismiss the overpricing allegations against the 12 Delhi hospitals?

The CCI dismissed the allegations because the evidence failed to prove abuse of dominance or unfair pricing. Additionally, the regulator emphasized that patients seek bundled healthcare services rather than isolated products.

Q2: What is the United Brands test used by the Commission?

The United Brands standard is a two-stage legal test. Specifically, it requires proving that a price is both excessive and unfair in itself before ruling it as an abuse of dominance.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Competition Commission closes case against 12 hospitals; rejects DG findings - ETHealthworld


2. Competition Commission of India Orders (May 2026)